Respiratory Syncytial Virus

Failed RSV Vaccine Due to Inability To Generate Antibody

Published in Vaccine Weekly, March 20th, 1995

Early failures of vaccines designed to prevent respiratory syncytial virus may have resulted from the inability of these vaccines to generate sufficient functional antibody, according to a report from Great Britain.

It has been a quarter of a century since the first attempts to develop vaccines to respiratory syncytial virus ended in failure. Neither formalin inactivated nor live virus vaccines, administered intramuscularly, provided significant protection for infants and both have been associated with enhanced rather than reduced severity of disease on subsequent natural infection.

There are currently a number of candidate vaccines for respiratory...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-03-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry